Bruns Ingmar's Form 4 filing
Zentalis Pharmaceuticals, Inc. (ZNTL) · filed Feb 10, 2026
- Accession no.
- 0001838041-26-000004
- Filed
- Feb 10, 2026
- Trade date
- Feb 6-9, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $8.00K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bruns IngmarCIK 0001838041 | Officer (Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 6, 2026 | Common Stock | SSaleDisposed | −2,962 | $2.43 | −$7,197.66 | 33,667 | Direct | |
| Feb 9, 2026 | Common Stock | SSaleDisposed | −335 | $2.39 | −$800.65 | 33,332 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.